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Effects of angiotensin converting enzyme inhibition in adult polycystic
kidney disease. The pathogenesis of hypertension in autosomal-domi-
nant polycystic kidney disease (ADPKD) is unclear, but increased
activity of the renin-angiotensin system may contribute. The renal and
systemic hemodynamic response to lisinopril, an angiotensin convert-
ing enzyme (ACE) inhibitor, in patients with ADPKD without renal
failure was compared with the response in matched unaffected family
members. Mean blood pressure and renal vascular resistance decreased
in the affected group after lisinopril, with no significant change in the
unaffected group. Glomerular filtration rate (GFR) was unchanged and
therefore filtration fraction fell significantly. Changes in urinary excre-
tion of 6-keto-PGF1 and kallikrein suggested that increased renal
synthesis of PGI2 or activation of the renal kallikrein-kinin system were
not likely to be responsible for the hemodynamic effects. The acute
decrease in renal vascular resistance without change in GFR suggests
that ACE inhibition may have a particular value in the treatment of
hypertension associated with ADPKD which should be assessed by
further long-term studies.
Hypertension is a common complication of autosomal dom-
inant polycystic kidney disease (ADPKD) which may develop
before the onset of detectable evidence of renal impairment
[1—4], but almost certainly accelerates the rate of deterioration
of renal function [5]. There is considerable controversy over the
mechanism of hypertension in ADPKD, but evidence points to
inappropriate activity of the renin-angiotensin system for the
state of extracellular fluid volume expansion [2, 6—91. At the
same time there may be increased dependence of the renal
circulation on activity of the renin-angiotensin system [9].
Acute inhibition of angiotensin converting enzyme provides a
means of assessing the significance of these factors for control
of both the renal and systemic circulation.
The relative contribution of different factors that accelerate
the decline in renal function in ADPKD are uncertain, but good
control of blood pressure probably provides the best opportu-
nity for limiting the rate of deterioration [10]. Since hyperten-
sion develops so early in the course of the illness, early and
effective blood pressure control may be particularly valuable.
Many drugs are available for blood pressure control, but there
is no evidence as to whether, by virtue of their particular renal
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hemodynamic profile, one type of drug has particular advan-
tages over other types.
In this study the acute effects of a single dose of lisinopril, an
angiotensin converting enzyme (ACE) inhibitor, on systemic
and renal hemodynamics was examined in a group of ADPKD
patients who were without significant renal failure and in
matched controls.
The effects of ACE inhibition on plasma renin activity,
urinary 6-keto-PGF1:. and kallikrein were also measured in an
attempt to clarify the mode of action.
Methods
Patients
Thirteen patients (8 male, 5 female) with ADPKD, mean age
32 (range 26 to 45 years), and 10 unaffected relatives (6 male, 4
female) with a mean age of 37 (range 23 to 47 years) were
studied. All affected subjects had ultrasound evidence of two or
more transonic cysts (greater than 0.5 cm in diameter) with
well-defined back walls, and some acoustic enhancement in one
kidney and at least a single cyst in the other. There were no
cysts in the kidneys of unaffected relatives on ultrasound, and
all subjects came from families with a history of ADPKD.
Individual details of renal function and blood pressure are
shown in Table 1. Genotypic studies were performed with a
3'HVR probe at the D16S85 locus near alpha globin on the short
arm of chromosome 16 [11]. In all subjects the genotype and
clinical phenotype of individuals was identical.
None of the patients had taken antihypertensive therapy for
at least two weeks before the study, although one patient had
previously been treated for mild hypertension. All subjects gave
their informed consent to participate. The research protocol
was approved by the local Ethical Committee of Lothian Health
Board.
Experimental protocol
Patients who were normotensive or mildly hypertensive
(sitting blood pressure < 150/95) with a plasma creatinine of less
than 150 p.mol/liter were admitted to the study. Each subject
collected urine for the 24 hours prior to the morning of the
study. They were admitted to the ward at 0830 hours having
fasted from the previous midnight, and were given 500 ml of
water to drink, followed by a further 100 ml every 30 minutes
for the rest of the study. Cannulae were placed in a forearm vein
of each arm and, after removal of a sample of blood, a loading
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dose of mutest (Laevosan, Gesellschaft, Linz, Austria) (50
mg/kg body wt) and paraaminohippurate (Merck, Sharp and
Dohme) (6 mg/kg body weight) was administered. An infusion
of mutest (20 mg/mm and p-aminohippurate 17 mg/mm) was
then maintained for the rest of the study. Subjects remained
recumbent throughout, except when standing to pass urine.
Blood pressure was monitored at 15 minute intervals with an
automated sphygmomanometer (Sentron, Bard Biomedical).
Alter a one-hour equilibration period the subjects voided
urine and two successive, timed urine collections of approxi-
mately 30 minutes were carried out (controls). Each subject
then received lisinopril 10 mg orally, and successive 30-minute
urine collections were continued for five hours. Blood samples
were collected at the beginning and end of each urine collection.
The specified dose of lisinopril has previously been demon-
strated to cause at least 75% inhibition of ACE activity within
the time course of this study [12].
Sample collection and analysis
All blood samples were collected on ice and centrifuged at
1500 g for 10 minutes to separate plasma. Samples for immedi-
ate analysis was stored at 4°C, and those for subsequent
analysis at —20°C.
Sodium, potassium and creatinine were measured in both
plasma and urine by routine laboratory techniques. Inulin and
p-aminohippurate were measured by an autoanalyzer method
[13, 14].
Previously described methods were used for analysis of
urinary kallikrein and 6-keto-prostaglandin F1, [15, 16]. Plasma
renin activity was measured using a radioimmunoassay system
(CIS Ltd.).
Calculation of results
Renal vascular resistance was calculated [17] from the equa-
(Mean BP — 12)
RYR )< 79680RBF
tion:
2 3 4
Renal vascular resistance (RVR) = Renal blood flow
The values for the control period were taken as the mean of
the two control urine collections. Statistical comparison was
made using analysis of variance to compare values obtained
during control periods and a specified time after administration
of drug, or when comparing affected and unaffected groups. All
results are expressed as mean SEM.
Results
Hemodynamics
Mean blood pressure during the control period was higher in
affected individuals (108.2 2.9 mm Hg) compared with
unaffected (88.6 2.7 mm Hg; P < 0.001; Fig. 1). Three and a
half hours after lisinopril there was a significant decrease in
blood pressure in the affected group (96.3 2.9; P < 0.01),
whereas the unaffected group showed an insignificant change
(81.8 2.8mm Hg; P = 0.099)at the same time, compared with
control. Maximal mean blood pressure change in the affected
group was 11.3 mm Hg and 6.8 mm Hg in the unaffected.
Clearance of inulin was not significantly different between the
two groups in the control period (affected 114.4 5.8 mllmin
vs. unaffected 106.1 7.3 mI/mm; NS) and there was no
consistent change in either group after lisinopril (Fig. 2). By
contrast, renal vascular resistance was significantly higher
during the control period in the affected patients (P <0.01; Fig.
2). Two and a half hours after lisinopril there was a significant
decrease in the affected patients (8123 753 to 5783 803
dyn. sec . cm5), but not in the unaffected (5548 452 to 4560
376 dyn. sec . cm5). Over the same period of time there
was a statistically significant decrease in filtration fraction in the
affected (0.22 0.05 to 0.18 0.04; P < 0.02) but not in the
unaffected (0.18 0.03 to 0.15 0.03; NS) groups.
Excretory function
Excretion of sodium in the 24 hours prior to the study was the
same in each group (affected 108 15, unaffected 122 20
mmol/24 hr).
Table 1. Systolic and diastolic blood pressure (mm Hg) and
clearance of inulin C10 during the control period in individual patients
and their unaffected relatives
E
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Fig. 1. Change in mean blood pressure in affected (— and unaf-
fected (— — —) groups. Mean blood pressure = systolic blood pressure +
1/3 pulse pressure.
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Fractional sodium excretion was no different during the
control period in affected (1.70 0.16 mmII24 hr) compared
with unaffected (1.94 0.24 mmolI24 br) patients. There was a
slight increase in the affected group after lisinopril, but this had
not achieved significance within four hours (affected 2.12 0.30
vs. unaffected 2.26 0.24 mmollhr; NS). Urinary potassium
excretion was unchanged in both groups after lisinopril.
Endocrine changes
Plasma ream activity was the same in the two groups before
treatment, although during the study activity tended to be
higher in the affected group at all times (Fig. 3). After lisinopril
there was a substantial increase in both groups, which was
highly significant after four hours (P < 0.001 in each group).
Urinary 6-keto-PGF1a was similar during the control period
in the two groups (Fig. 4) and decreased transiently after
lisinopril; similarly, urinary kallikrein excretion tended to de-
crease to a minimum level two hours after the drug, before
again increasing.
Fig. 3. Plasma
groups.
t Lisinopril
C 1 2 3 4 5
Time, hours
renin activity in affected (—) and unaffected (— — —)
Discussion
Angiotensin converting enzyme inhibitors combine the role
of useful therapeutic agents and tools to examine the patho-
physiological role of the renin-angiotensin system in different
circulatory disorders [18]. Comparison of the renal hemody-
namic response to lisinopril of affected and unaffected family
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members provides similar results to those reported using enal-
april in a comparison of polycystic and essential hypertensive
patients [9].
A number of hypotheses may be advanced to account for the
hemodynamic response to ACE inhibition. The most simple
explanation is that enhanced activity of the renin-angiotensin
system has a pivotal role both for raising blood pressure and for
reducing renal vascular resistance in ADPKD. The substantial
hypotensive effect of lisinopril in mildly hypertensive patients
occurred despite a marginal difference in plasma renin activity
compared to unaffected members. This is consistent with other
studies, suggesting that although PRA is not elevated, the level
of activity of the renin-angiotensin system is inappropriate for
the state of the extracellular fluid volume [7, 8]. An attractive
explanation for such an effect in ADPKD is that excessive
intra-renal activity of the renin-angiotensin system mediates
both sodium retention and enhanced renal vascular resistance
[19]. The gradual expansion of the cysts within the renal
parenchyma may result in compression of adjacent renal tis-
sues, activation of the juxtaglomerular apparatus (JGA) and
local release of renin, either by a direct effect or by restriction
of the afferent blood supply to the JGA [20, 21]. The cystic
kidney could therefore be considered as having islands of
relative ischemia adjacent to cysts, with associated activation
of angiotensin II production. This would in turn vasoconstrict
both afferent and efferent arterioles and promote sodium reten-
tion either directly [22], or through its hemodynamic effect [23].
In such circumstances the ACE inhibitor would have the acute
effect of both dilating a section of renal vasculature, and
promoting sodium excretion. Both of these effects may only be
occurring in a limited proportion of the total nephron popula-
tion. Glomerular filtration rate does not change, suggesting that
the ACE inhibitor is having a similar effect on afferent and
efferent arteriolar tone.
The same effect on renal hemodynamics and sodium excre-
tion is, however, observed when patients with essential hyper-
tension are given an ACE inhibitor [24], although to a less
extent than in ADPKD [9]. Focal areas of ischemia are less
likely to be the explanation in this instance, and therefore other
potential explanations must be sought. ACE inhibitors are
reported to stimulate renal prostaglandin synthesis under cer-
tain conditions [25, 26]. PGE2 and PG!2 are both potent renal
vasodilators and natnuretic compounds [27], so that increased
synthesis in this study could provide a potential explanation for
the observed hemodynamic responses [25].
The urinary excretion of 6-keto-PGF1, the stable metabolite
of PGI.,, diminished after lisinopril administration. Urinary
6-keto-PGF1, provides a measure of PG!2 synthesis in certain
sites in the kidney [28, 29]; a fall in production following ACE
inhibition in the present study argues against a significant role.
Urinary PGE was also measured in the same patients; there was
a wide scatter of results because of methodological difficulties
in collecting uncontaminated urine specimens [30], but there
was certainly no significant increase. The available evidence
does not therefore support a role for prostaglandins.
Inhibition of ACE also inhibits degradation of bradykinin.
Increased activity of the kallikrein-kinin system has been in-
voked as another mediator of the effects of ACE inhibition in
view of its vasodilator effect [31, 32]. Urinary kallikrein pro-
vides a crude measure of renal kallikrein-kinin activity [33]. The
observed fall in kallikrein excretion after ACE inhibition in our
studies, although not exclusive, does not support a role for
activation of renal kinins. In the absence of causal changes in
prostaglandins or kinins, intra-renal activation of angiotensin II
synthesis remains the most likely explanation of our findings.
The hemodynamic response to ACE inhibition encourages the
hope that this type of drug will have significant advantages as
hypotensive agents in ADPKD. Detailed hemodynamic studies
of beta blockers in patients with renal impairment suggest that
they do not have the same potentially beneficial effects on the
kidney that we have observed with ACE inhibition [34, 35].
Similar results have also been found in a comparison of ACE
inhibitors and beta blockers in essential hypertension [36].
Whether or not the acute hemodynamic effects are sustained in
the long term treatment of hypertension in ADPKD is unknown
and merits further study. In particular, it will be important to
find out whether drugs with this mode of action delay the
deterioration of renal function, in comparison with other agents
that have similar hypotensive efficacy [37].
In conclusion, the response to lisinopril provides evidence for
a role of the renin-angiotensin system in the genesis of hyper-
tension in ADPKD. A detailed assessment of the long-term
value of ACE inhibition in limiting the rate of deterioration of
renal function in ADPKD is now required.
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